Department for Otolaryngology and Head and Neck surgery.
Department for radiotherapy and oncology.
Medicine (Baltimore). 2021 Jan 22;100(3):e23943. doi: 10.1097/MD.0000000000023943.
To investigate whether laryngeal cancer cells express erythropoietin (Epo) and erythropoietin receptor (EpoR) and what is their possible relationship with clinical and pathological features of the tumor.We performed immunohistochemical analysis of Epo and EpoR expression on 78 tissue samples of invasive and in situ squamous cell laryngeal carcinoma.The statistical analysis showed a weak positive and statistically significant correlation of EpoHS and EpoR HS expression levels. Epo HS and EpoR HS levels did not correlate with patient sex or age, type of diagnosis, cancer stage, histological tumor grade, presence or absence of disease recurrence, type of oncologic cancer therapy provided, or results of selected laboratory blood work. The results show a statistically significant difference in Epo expression with respect to survival.We confirmed the presence of Epo an EpoR in malignant laryngeal tumors and demonstrated the correlation between Epo expression and survival. Further studies are needed to more precisely define the role of Epo and EpoR in treatment of patients with laryngeal cancer.
为了研究喉癌细胞是否表达促红细胞生成素(Epo)和促红细胞生成素受体(EpoR),以及它们与肿瘤的临床和病理特征有何关系。我们对 78 例浸润性和原位鳞状细胞喉癌组织标本进行了 Epo 和 EpoR 表达的免疫组织化学分析。统计分析显示 EpoHS 和 EpoR HS 表达水平呈弱阳性且具有统计学意义的相关性。EpoHS 和 EpoR HS 水平与患者性别或年龄、诊断类型、癌症分期、组织学肿瘤分级、疾病复发与否、提供的肿瘤治疗类型或选定的实验室血液检查结果无关。结果显示,Epo 的表达与生存率有统计学显著差异。我们证实了恶性喉肿瘤中存在 Epo 和 EpoR,并证明了 Epo 表达与生存之间的相关性。需要进一步研究以更精确地定义 Epo 和 EpoR 在治疗喉癌患者中的作用。